2C-T-27, also known as 4-benzylthio-2,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and 2C families.
2C-T-27 has been reported to produce hallucinogenic effects in humans. Its dose was reported by Daniel Trachsel to be 80mg or more orally and no duration was listed.
In addition to the serotonin 5-HT<sub>2A</sub> receptor, 2C-T-27 interacts with the serotonin 5-HT<sub>2C</sub> receptor. It showed higher affinity for the serotonin 5-HT<sub>2A</sub> receptor than any other 2C drug (K<sub>i</sub> = 1.6nM), but its activational potency and efficacy were among the lowest ( = 26nM; = 27%).
The drug produces the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in rodents. However, the HTR induced by 2C-T-27 is relatively weak.
Analogues of 2C-T-27 include 2C-T-6 and 2C-T-33, among others.
2C-T-27 was first synthesized and described by Daniel Trachsel in 2003.
2C-T-27 is a controlled substance in Canada under phenethylamine blanket-ban language.